Clinical trial
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the…
NCT00041808 · FeRx, Industry · Completed
Key facts
| NCT number | NCT00041808 |
|---|---|
| Title | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver |
| Official title | A Phase I/II Single Dose Trial to Determine The Safety, Tolerance, Pharmacokinetic Profile, and Preliminary Activity of Intrahepatic Delivery (Via Hepatic Artery Catheterization) of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers ( MTC-DOX) in Patients With Metastatic Cancer to the… |
| Lead sponsor | FeRx, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms and 3 more |
| Intervention type | Drug, Procedure |
| Interventions | MTC-DOX for Injection, Chemotherapy |
| Enrollment | 20 |
| Start date | Jul 1, 2001 |
| Completion | Apr 1, 2003 |
| First posted | Jul 19, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | Germany, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: